IGC Pharma, Inc.
For the period ended Sep 30, 2026. Filed Nov 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
On October 22, 2026, the Company and each of Mr. Ram Mukunda and Ms. Claudia Grimaldi amended the Stock Purchase Agreements dated June 30, 2026, as described in Note 17, “Subsequent Events,” which is incorporated herein by reference. A copy of the amendment is filed as Exhibit 10.12 to this report.
Other than disclosed above, during the three months ended September 30, 2026, no director or officer of the Company adopted orterminated any contract, instruction or written plan for the purchase or sale of Company securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K.
| September 30, 2026, Form 10-Q
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.